Full text is available at the source.
Advancements in RNA-targeted therapies for renal cell carcinoma
New RNA-based treatments for kidney cancer
AI simplified
Abstract
Elevated mortality rates in renal cell carcinoma (RCC) are primarily due to resistance to traditional therapies.
- Recent RNA-targeted therapies may enhance the effectiveness of treatments for RCC.
- Innovative strategies include antisense oligonucleotides, small interfering RNAs, and CRISPR/Cas9.
- These therapies are associated with high specificity and effectiveness in preclinical models.
- There is a focus on personalized medicine to optimize outcomes for RCC patients.
- Advancements in delivery mechanisms could improve the integration of these therapies with current treatments.
AI simplified